DOI: http://dx.doi.org/10.18203/2349-3933.ijam20220442

Utility and benefits of sulfonylureas beyond glycemic control

Jayakrishnan B.

Abstract


Department of medicine, Educare institute of dental science Malappuram, Kerala and SafeCare clinics, Tirur, Kerala sulfonylureas (SUs) are one of the oldest, time tested and most commonly used oral antidiabetic agent in Type 2 diabetes. Modern SUs like glimepiride and gliclazide XR were preferred over conventional SUs due to its better efficacy and minimal side effects. The use of Modern SUs in the treatment armamentarium of T2DM has evolved, over past few decades. Modern SUs possesses beneficial pancreatic glucose lowering effect and more interestingly extra-pancreatic pleiotropic benefits. This review article discusses on the utility and benefits of SUs beyond glycemic control and explaining on their pleiotropic effects.


Keywords


SUs, Pleiotropic, Glimepiride, Gliclazide, Adiponectin

Full Text:

PDF

References


IDF Diabetes Atlas. 10th Edition. Available at: https://diabetesatlas.org/idfawp/resource-files/2021/07/IDF_Atlas_10th_Edition_2021.pdf. Accessed on 24 January 2022

Consoli A, Czupryniak L, Duarte R. Positioning sulphonylureas in a modern treatment algorithm for patients with type 2 diabetes: Expert opinion from a European consensus panel. Diabetes Obes Metab. 2020;22(10):1705-13.

Hirst JA, Farmer AJ, Dyar A, Lung TW, Stevens RJ. Estimating the effect of sulfonylurea on HbA1c in diabetes: A systematic review and meta‑analysis. Diabetologia. 2013;56:973‑84.

Inukai K, Watanabe M, Nakashima Y. Efficacy of glimepiride in Japanese type 2 diabetic subjects. Diabetes Res Clin Pract. 2005;68(3):250-7.

Müller G, Satoh Y, Geisen K. Extrapancreatic effects of sulfonylureas-A comparison between glimepiride and conventional sulfonylureas. Diabetes Res Clin Pract. 1995;28:S115-37.

Briscoe VJ, Griffith ML, Davis SN. The role of glimepiride in the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol. 2010;6:225-35.

Bonfilio R, De Araújo MB, Salgado HR. A review of analytical techniques for determination of glimepiride: Present and perspectives. Ther Drug Monit. 2010;32:550-9.

Aleidi S, Issa A, Bustanji H. Adiponectin serum levels correlate with insulin resistance in type 2 diabetic patients. Saudi Pharm J. 2015;23(3):250-6.

Abdella NA, Mojiminiyi OA. Clinical Applications of Adiponectin Measurements in Type 2 Diabetes Mellitus: Screening, Diagnosis, and Marker of Diabetes Control. Dis Markers. 2018.

Nagasaka S, Taniguchi A, Aiso Y. Effect of glimepiride on serum adiponectin level in subjects with type 2 diabetes. Diabetes Care. 2003;26:2215-6.

Kalra S, Aamir AH, Raza A. Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A consensus statement. Indian J Endocrinol Metab. 2015;19:577-96.

Li CJ, Zhang JY, Yu DM. Adding glimepiride to current insulin therapy increases high-molecular weight adiponectin levels to improve glycemic control in poorly controlled type 2 diabetes. Diabetol Metab Syndr. 2014;20;6(1):41.

Araki T, Emoto M, Konishi T. Glimepiride increases high-density lipoprotein cholesterol via increasing adiponectin levels in type 2 diabetes mellitus. Metabolism. 2009;58(2):143-8.

Barzilai N, Groop PH, Groop L, DeFronzo RA. A novel mechanism of glipizide sulfonylurea action: decreased metabolic clearance rate of insulin. Acta Diabetol. 1995;32(4):273-8.

Kalra S, Ghosh S, Das AK, Nair T. Unravelling the utility of modern sulfonylureas from cardiovascular outcome trials and landmark trials: expert opinion from an international panel. Indian Heart J. 2020;72(1):7-13.

Mocanu MM, Maddock HL, Baxter GF, et al. Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. Circulation. 2001;103(25):3111-6.

Rados DV, Pinto LC, Remonti LR. The association between sulfonylurea use and all-cause and cardiovascular mortality: A meta-analysis with trial sequential analysis of randomized clinical trials. PLOS Medicine. 2016;3:43-51.

Aravind SR, Mittal S, Venkatraman S. Cardiovascular Profile of Modern Sulfonylureas: Focus on Glimepiride. J Association Physicians India. 2019;67:17-9.

Vaccaro O, Masulli M, Nicolucci A. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): A randomised, multicentre trial. Lancet Diabetes Endocrinol. 2017;5(11):887-97.

Rosenstock J, Perkovic V, Johansen OE. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA. 2019;321(1):69-79.

Nakamura I, Oyama J, Komoda H. Possible effects of glimepiride beyond glycemic control in patients with type 2 diabetes: A preliminary report. Cardiovasc Diabetol. 2014;13:15.

Kalra S, Das AK, Baruah MP. Glucocrinology of Modern Sulfonylureas: Clinical Evidence and Practice-Based Opinion from an International Expert Group. Diabetes Ther. 2019;10(5):1577-93.

Wong L, Chen H-M, Lai S-Q. Effects of sulfonylurea as initial treatment on testosterone of middle-aged men with type 2 diabetes: A 16-week, pilot study. J Diabetes Investig. 2015;6(4):454-9.